A phase I, multi-center, open label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of orally administered SGX523, a small molecule anti-cancer agent, on a twice daily, interrupted schedule in patients with advanced cancer

Trial Profile

A phase I, multi-center, open label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of orally administered SGX523, a small molecule anti-cancer agent, on a twice daily, interrupted schedule in patients with advanced cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2008

At a glance

  • Drugs SGX 523 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SGX Pharmaceuticals
  • Most Recent Events

    • 22 Jul 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Mar 2008 Dose limiting toxicity was observed earlier than anticipated; no patients are currently being treated in the interrupted dose trial.
    • 21 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top